海正藥業(600267.SH):阿託伐他汀鈣片獲藥品註冊證書
格隆匯2月4日丨海正藥業(600267.SH)公佈,近日,公司收到國家藥監局核准簽發的阿託伐他汀鈣片的《藥品註冊證書》。
阿託伐他汀鈣片適用於高膽固醇血癥和冠心病的治療。阿託伐他汀鈣製劑由美國華納蘭伯特製藥公司(現併入輝瑞公司)研製成功,商品名為Lipitor(立普妥),是輝瑞公司旗下重要品種。截至目前,公司在阿託伐他汀鈣片研發項目上已投入約2633萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.